160 related articles for article (PubMed ID: 38067507)
1. Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOC Cells.
Merve Aydin E; Canıtez İS; Colombo E; Princiotto S; Passarella D; Dallavalle S; Christodoulou MS; Durmaz Şahin I
Molecules; 2023 Nov; 28(23):. PubMed ID: 38067507
[TBL] [Abstract][Full Text] [Related]
2. Molecular Docking Study, Cytotoxicity, Cell Cycle Arrest and Apoptotic Induction of Novel Chalcones Incorporating Thiadiazolyl Isoquinoline in Cervical Cancer.
Tantawy MA; Sroor FM; Mohamed MF; El-Naggar ME; Saleh FM; Hassaneen HM; Abdelhamid IA
Anticancer Agents Med Chem; 2020; 20(1):70-83. PubMed ID: 31696811
[TBL] [Abstract][Full Text] [Related]
3. Chalcones: Promising therapeutic agents targeting key players and signaling pathways regulating the hallmarks of cancer.
WalyEldeen AA; Sabet S; El-Shorbagy HM; Abdelhamid IA; Ibrahim SA
Chem Biol Interact; 2023 Jan; 369():110297. PubMed ID: 36496109
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour activity of a novel coumarin-chalcone hybrid is mediated through intrinsic apoptotic pathway by inducing PUMA and altering Bax/Bcl-2 ratio.
Singh N; Sarkar J; Sashidhara KV; Ali S; Sinha S
Apoptosis; 2014 Jun; 19(6):1017-28. PubMed ID: 24638227
[TBL] [Abstract][Full Text] [Related]
5. Chalcones against the hallmarks of cancer: a mini-review.
de Souza PS; Bibá GCC; Melo EDDN; Muzitano MF
Nat Prod Res; 2022 Sep; 36(18):4809-4826. PubMed ID: 34865580
[TBL] [Abstract][Full Text] [Related]
6. Natural Chalcones and Their Derivatives Target the Tumor Microenvironment in Colon Cancer.
Malla RR; Siragam S; Dadi V; Seetini B
Crit Rev Immunol; 2022; 42(6):27-39. PubMed ID: 37082949
[TBL] [Abstract][Full Text] [Related]
7. A novel synthetic chalcone derivative, 2,4,6-trimethoxy-4'-nitrochalcone (Ch-19), exerted anti-tumor effects through stimulating ROS accumulation and inducing apoptosis in esophageal cancer cells.
Yang Y; Wu H; Zou X; Chen Y; He R; Jin Y; Zhou B; Ge C; Yang Y
Cell Stress Chaperones; 2022 Nov; 27(6):645-657. PubMed ID: 36242757
[TBL] [Abstract][Full Text] [Related]
8. Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents
Su Q; Xu B; Tian Z; Gong Z
Acta Pharm; 2022 Sep; 72(3):389-402. PubMed ID: 36651540
[TBL] [Abstract][Full Text] [Related]
9. Tetramethoxychalcone, a chalcone derivative, suppresses proliferation, blocks cell cycle progression, and induces apoptosis of human ovarian cancer cells.
Qi Z; Liu M; Liu Y; Zhang M; Yang G
PLoS One; 2014; 9(9):e106206. PubMed ID: 25180593
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of trans-chalcone and licochalcone A against breast cancer cells is due to apoptosis induction and cell cycle arrest.
Bortolotto LF; Barbosa FR; Silva G; Bitencourt TA; Beleboni RO; Baek SJ; Marins M; Fachin AL
Biomed Pharmacother; 2017 Jan; 85():425-433. PubMed ID: 27903423
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships reveal a 2-furoyloxychalcone as a potent cytotoxic and apoptosis inducer for human U-937 and HL-60 leukaemia cells.
Del Rosario H; Saavedra E; Brouard I; González-Santana D; García C; Spínola-Lasso E; Tabraue C; Quintana J; Estévez F
Bioorg Chem; 2022 Oct; 127():105926. PubMed ID: 35717804
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and bioevaluation of novel prenylated chalcones derivatives as potential antitumor agents.
Yu J; Wang X; Cheng S; Zeng X; Wan X; Wei S; Xu B; Luo H; Meng X
Eur J Pharm Sci; 2024 Jan; 192():106660. PubMed ID: 38052256
[TBL] [Abstract][Full Text] [Related]
13. Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease.
Haley J; Tomar S; Pulliam N; Xiong S; Perkins SM; Karpf AR; Mitra S; Nephew KP; Mitra AK
Oncotarget; 2016 May; 7(22):32810-20. PubMed ID: 27147568
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, and Anti-Cervical Cancer and Reversal of Tumor Multidrug Resistance Activity of Novel Nitrogen-Containing Heterocyclic Chalcone Derivatives.
Yang Z; Liu ZY; Ablise M; Maimaiti A; Mutalipu Z; Alimujiang Y; Aihaiti A
Molecules; 2023 Jun; 28(11):. PubMed ID: 37299013
[TBL] [Abstract][Full Text] [Related]
15. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3',4',5'-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities.
Srinivasan B; Johnson TE; Lad R; Xing C
J Med Chem; 2009 Nov; 52(22):7228-35. PubMed ID: 19883086
[TBL] [Abstract][Full Text] [Related]
17. Chalcone Derivatives: Role in Anticancer Therapy.
Ouyang Y; Li J; Chen X; Fu X; Sun S; Wu Q
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208562
[TBL] [Abstract][Full Text] [Related]
18. Structure optimization of an F-indole-chalcone (FC116) on 4-methoxyphenyl group and therapeutic potential against colorectal cancers with low cytotoxicity.
Du B; Liu X; Luan X; Zhang W; Zhuang C
Bioorg Chem; 2023 Jun; 135():106531. PubMed ID: 37043882
[TBL] [Abstract][Full Text] [Related]
19. Chalcone Derivatives and their Activities against Drug-resistant Cancers: An Overview.
Xiao J; Gao M; Diao Q; Gao F
Curr Top Med Chem; 2021; 21(5):348-362. PubMed ID: 33092509
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Apoptosis-Promoting Effect Evaluation of Chalcone Derivatives Containing Aminoguanidine Units.
Wang Y; Li L; Ma T; Cheng X; Liu D
Anticancer Agents Med Chem; 2022; 22(11):2116-2124. PubMed ID: 34702155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
